The detection of fibrinogen/fibrin degradation products by means of a new antibody-coated latex particle

M. BERNADETTE GARVEY AND JOAN M. BLACK
From St Michael’s Hospital and the Department of Medicine, University of Toronto, Canada

SYNOPSIS A rapid slide test for the detection of degradation products of fibrinogen/fibrin (FDP) using a new antibody-coated latex particle is described. The latex particle has been specifically coated with antibody to fragments D and E. The latex agglutination test (Thrombo-Wellcotest) has been compared with the tanned red cell haemagglutination inhibition immunoassay (TRCHII) in 143 patients with a variety of clinical conditions. There is a high degree of agreement between the methods with a coefficient of correlation of 0.83. The method provides a rapid, simple screening test for fibrin degradation products.

Several methods are presently available for measuring products of fibrinogen/fibrin degradation by plasmin. The demonstration of these products constitutes a valuable means of detecting consumption coagulopathy or primary fibrinolysis. The most widely used techniques are the TRCHII (Merskey, Kleiner, and Johnson, 1966), immunodiffusion, and immunoelectrophoresis (Nussenzweig, Seligmann, and Grabar, 1961; Niléhn and Nilsson, 1964; Ferreira, Murat, and Ferri, 1964; Fisher, Fletcher, Alkjaersig, and Sherry, 1967), precipitin tests ( Hirsh, Fletcher, and Sherry, 1965; Stiehm and Trygstad, 1969), the staphylococcal clumping test ( Lipinski, Hawiger, and Jeljaszewicz, 1967; Hawiger, Niewiarowski, Gurewich, and Allington, 1967; Thomas, 1970), and agglutination of latex particles (FI) ( Thomas, Niewiarowski, Myers, Bloch, and Colman, 1970; Marder, Matchett, and Sherry, 1971). A comparative study of the commonly used methods has recently been reported by Thomas et al (1970) who found a good correlation between the results obtained using the staphylococcal clumping test, the TRCHII, and the latex agglutination test. Each of these methods has limitations for widespread use in clinical situations requiring rapid results. Immunodiffusion requires a 48-hour incubation period and appears to be insensitive to values below 40 µg/ml. The staphylococcal clumping test and the TRCHII are time consuming and technically demanding. Agglutination of antibody-coated latex particles provides a simple rapid screening method for the detection of fibrinogen/fibrin degradation products. However, the presently available FI test has been reported to give a high degree of negative results ( Castelan, Hirsh, and Martin, 1968; Thomas et al, 1970; Cohen, 1970). Thomas et al (1970) have suggested that this may be due to the fact that the FI test is not sensitive to fragment E.

A new antibody-coated latex particle Thrombo-Wellcotest, coated specifically with anti-D and anti-E, is now available. We have compared the use of Thrombo-Wellcotest with the TRCHII.

Materials and Methods

The latex particles were supplied by the Wellcome Research Laboratory and were prepared in the following manner as described by Pitcher (1971).

Purified human fibrinogen was digested by the enzyme plasmin to give stage 3 degradation products—fragments D and E. These were separated from contaminants by agarose gel electrophoresis, mixed in equal quantities, emulsified in adjudvant, and injected into rabbits. The resulting immune serum was absorbed with a solid polymer of normal human serum (Avrameas and Ternynck, 1969) containing negligible amounts of FDP to remove any cross reactions to other serum proteins. Specific globulins were extracted and used to sensitize latex particles to give a rapid slide test sensitive to 2 µg/ml of fibrinogen.

One hundred and forty-three sera from patients with a variety of pathological conditions were evaluated. Five millilitres of venous blood was
Detection of fibrinogen/fibrin degradation products by a new antibody-coated latex particle

collected by means of a plastic disposable syringe and a 20 gauge needle. The blood was transferred to a glass test tube containing 0.1 ml of Trasylol® (5000 u/ml) and incubated in a water bath at 37°C for two hours. After incubation the specimen was centrifuged at 3000 rpm for 10 minutes and the serum removed. The whole volume of serum was mixed with one-tenth of its volume of a solution of thrombin® containing 100 u/ml. The serum-thrombin mixture was incubated for 30 to 60 minutes, again centrifuged and stored at −70°C in 1 ml aliquots.

The serum was thawed at 37°C and dilutions of 1 in 4, 1 in 16, and 1 in 64 were made in glycinesaline buffer pH 8.2. The latex agglutination tests were performed on opaque glass plates similar to those used in latex particle pregnancy tests. One drop of each serum dilution was added to one drop of latex particle suspension and mixed by means of an applicator stick. Standardized drops were delivered from microhaematocrit capillary tubes. The plate was rotated gently for two minutes and the reaction was timed with a stop watch.

Positive reactions showed macroscopically visible agglutination in less than two minutes. High titre sera were found to give positive results more rapidly than those with low titres.

A 10 µg/ml fibrinogen standard provided by the Wellcome Research Laboratory was used as a control. The latex agglutination test gave a positive reaction at a fibrinogen concentration of 2.0 µg/ml.

In determining the relationship between the rapid slide test and the FDP titre, quantitative estimations were performed by means of the Wellcome FDP kit, which employs the TRCHII technique of Merskey et al (1966). The normal range in our laboratory is 0 to 10 µg/ml.

Results

The results are tabulated in the Figure. There is very close agreement between the results obtained using the latex particle agglutination test and the TRCHII. Using the criterion outlined in the Table there is absolute agreement between the two methods in 100 of 143 cases. The coefficient of correlation is 0.833. In 10

<table>
<thead>
<tr>
<th>Serum Dilution</th>
<th>FDP Range (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/4</td>
<td>1/16</td>
</tr>
<tr>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>Pos</td>
<td>Neg</td>
</tr>
<tr>
<td>Pos</td>
<td>Pos</td>
</tr>
<tr>
<td>Pos</td>
<td>Pos</td>
</tr>
</tbody>
</table>

Table Results with Thrombo-Wellcotest

Fig.  Relationship between the FDP assay and the FDP screening test in various pathological conditions.
cases the latex agglutination test gave results slightly lower than those demonstrated by the TRCHII. In 31 cases the results obtained by the latex agglutination test were slightly higher than those detected by the TRCHII, indicating that in these cases the latex agglutination test was slightly more sensitive. Of these 41 cases, 35, or 85%, were at levels not greater than 20 μg/ml, and therefore not considered to be in a clinically significant range. In only two of the 143 cases was there a discrepancy of more than 1 dilution. In one case, high levels of cryofibrinogen appeared to obscure the results in the TRCHII. The second case represented a patient with an acute rejection of a renal transplantation. The TRCHII gave a level significantly higher than the latex agglutination test. We have no explanation for this discrepancy.

Discussion

The use of the latex particles coated with antibody to the late products of fibrin degradation, fragments D and E, constitutes a simple and rapid screening technique for the detection of fibrinogen/fibrin degradation products. The correlation between Thrombo-Wellcotest and the established TRCHII is extremely good. From this study it would appear that the latex particle method is useful in identifying very low levels of degradation products and can be used with a high degree of accuracy as a screening procedure.

The Thrombo-Wellcotest was supplied by Warner-Chilcott Laboratories, Toronto. Their support is gratefully acknowledged.

References


The detection of fibrinogen/fibrin degradation products by means of a new antibody-coated latex particle

M. Bernadette Garvey and Joan M. Black

doi: 10.1136/jcp.25.8.680

Updated information and services can be found at:
http://jcp.bmj.com/content/25/8/680

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/